Clinical Trials Directory

Trials / Completed

CompletedNCT04866004

Contingency Management for Cannabis Use for Persons With HIV

Feasibility and Impact of 28-days of Monitored Abstinence From Cannabis Use on Symptoms of Distress, Inflammation, and HIV Viral Load

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
25 (actual)
Sponsor
The University of Texas Health Science Center at San Antonio · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine the feasibility and impact of 28-days of monitored abstinence from cannabis use on symptoms of depression and anxiety, pain, sleep, cannabis use withdrawal, HIV viral load and biomarkers of systemic inflammation among PLWH and who use cannabis regularly (weekly or more often). This will be a single arm pilot feasibility trial involving a contingency management program to induce cannabis abstinence. Specifically, the contingency management program will provide motivational (monetary) incentives to participants who achieve biochemically verified cannabis abstinence. Over the 28-days of this pilot feasibility trial, participants will attend seven study visits. During these visits, participants will complete survey questionnaires to assess sociodemographic, psychosocial, and behavioral factors. In addition, participants will provide blood and urine specimens for testing and quantitation of HIV viral load, biomarkers of systemic inflammation and for the detection of cannabis and other drugs of abuse.

Conditions

Interventions

TypeNameDescription
BEHAVIORALContingency Management - CannabisParticipants in the contingency management program will be provided financial incentives for 28-days of cannabis abstinence. At every visit, participants will provide urine samples for the biochemical verification of cannabis abstinence). Participants with evidence of cannabis abstinence will be provided a financial incentive that increases across subsequent study visits.

Timeline

Start date
2021-08-01
Primary completion
2025-07-31
Completion
2025-07-31
First posted
2021-04-29
Last updated
2025-09-04

Locations

2 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT04866004. Inclusion in this directory is not an endorsement.